Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models

Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded lipos...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & therapy Vol. 15; no. 1; pp. 69 - 80
Main Authors Apte, Anjali, Koren, Erez, Koshkaryev, Alexander, Torchilin, Vladimir P
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2014
Landes Bioscience
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox ® , a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG 1000 -PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG 2000 -Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of "smart" multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future.
AbstractList Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox ® , a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG 1000 -PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG 2000 -Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of “smart” multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future.
Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have previously described the physicochemical characteristics and the in vitro anticancer properties of a multifunctional doxorubicin-loaded liposomal formulation. Lipodox(®), a commercially available PEGylated liposomal doxorubicin, was made multifunctional by surface-decorating with a cell-penetrating peptide, TATp, conjugated to PEG 1000-PE, to enhance liposomal cell uptake. A pH-sensitive polymer, PEG 2000-Hz-PE, with a pH-sensitive hydrazone (Hz) bond to shield the peptide in the body and expose it only at the acidic tumor cell surface, was used as well. In addition, an anti-nucleosome monoclonal antibody 2C5 attached to a long-chain polymer to target nucleosomes overexpressed on the tumor cell surface was also present. Here, we report the in vitro cell uptake and cytotoxicity of the modified multifunctional immunoliposomes as well as the in vivo studies on tumor xenografts developed subcutaneously in nude mice with MDR and drug-sensitive human ovarian cancer cells (SKOV-3). Our results show the ability of multifunctional immunoliposomes to overcome MDR by enhancing cytotoxicity in drug-resistant cells, compared with non-modified liposomes. Furthermore, in comparison with the non-modified liposomes, upon intravenous injection of these multifunctional immunoliposomes into mice with tumor xenografts, a significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug-resistant and drug-sensitive mice was obtained. The use of "smart" multifunctional delivery systems may provide the basis for an effective strategy to develop, improve, and overcome MDR cancers in the future.
Author Koren, Erez
Apte, Anjali
Torchilin, Vladimir P
Koshkaryev, Alexander
Author_xml – sequence: 1
  givenname: Anjali
  surname: Apte
  fullname: Apte, Anjali
– sequence: 2
  givenname: Erez
  surname: Koren
  fullname: Koren, Erez
– sequence: 3
  givenname: Alexander
  surname: Koshkaryev
  fullname: Koshkaryev, Alexander
– sequence: 4
  givenname: Vladimir P
  surname: Torchilin
  fullname: Torchilin, Vladimir P
  email: v.torchilin@neu.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24145298$$D View this record in MEDLINE/PubMed
BookMark eNplkcuOFCEUhokZ41x04QsYlrqoESioy8ZkMl6TSdy0a8LlVM8xVdAC1dpv5GPK2ONEY0LC5f_Oz4H_nJyEGICQ55xdSt7x186WS9F1bHxEzrhSqhlU353crduhkUz2p-Q856-MiV504xNyKiSXSozDGfn5Nv6IabXoMNA6NlcbuoNdQQ_NEj1OCJ4u61xwWoMrGIOZKS7LGuKMu5jjApl6WGLIJZlSNxhcApNrman8HsuBmq3BqlMbyy31ad02GULGqgI1wR-PEmTMxYRC494kNIE6ExwkWtuAOT8ljyczZ3h2P1-QL-_fba4_NjefP3y6vrppnBSsNKNyXhjjO6fADqzj3E6y4zD0XjAhpbWOwciByaEF3_YTTNxy1feTG4Qd-_aCvDn67la7gHcQ6rtmvUu4mHTQ0aD-Vwl4q7dxr9uxHZRQ1eDlvUGK31bIRS-YHcyzCRDXrLkc237sOiUq-uqIuhRzTjA9XMOZvktW12T172Qr--Lvvh7IP1FWQB4BDFNMi_ke0-x1MYc5pinVr8Ss2_99fwHpALox
CitedBy_id crossref_primary_10_1002_bip_22678
crossref_primary_10_4161_tisb_29528
crossref_primary_10_1007_s10529_014_1497_2
crossref_primary_10_2174_1566523223666230601145632
crossref_primary_10_2174_1573394716666200227095521
crossref_primary_10_1007_s13204_018_0776_y
crossref_primary_10_1021_acsami_5b06488
crossref_primary_10_1016_j_jconrel_2022_08_001
crossref_primary_10_1080_01635581_2015_1002624
crossref_primary_10_3390_ph12020081
crossref_primary_10_1007_s11705_015_1538_y
crossref_primary_10_1021_acsnano_8b06104
crossref_primary_10_3923_ijp_2022_70_78
crossref_primary_10_3390_ijms21114138
crossref_primary_10_1007_s40495_016_0056_z
crossref_primary_10_1016_j_ijpharm_2015_04_059
crossref_primary_10_1080_10717544_2018_1435747
crossref_primary_10_1517_17425247_2016_1125879
crossref_primary_10_1016_j_colsurfb_2015_07_013
crossref_primary_10_1016_j_nano_2020_102309
crossref_primary_10_1016_j_mtbio_2022_100248
crossref_primary_10_1089_cbr_2018_2447
crossref_primary_10_2174_1567201817666200708113131
crossref_primary_10_1016_j_xphs_2021_08_015
crossref_primary_10_1517_17425247_2015_1086745
crossref_primary_10_1007_s13346_018_00606_x
crossref_primary_10_1016_j_jics_2021_100119
crossref_primary_10_3390_pharmaceutics13091391
crossref_primary_10_3390_ijms19030731
crossref_primary_10_1016_j_ijpharm_2020_120117
crossref_primary_10_1016_j_jconrel_2023_09_016
crossref_primary_10_1038_nrd4333
crossref_primary_10_1080_17425247_2017_1247804
crossref_primary_10_3390_pr7100727
crossref_primary_10_1016_j_xphs_2018_12_016
crossref_primary_10_1016_j_jconrel_2016_02_008
crossref_primary_10_1016_j_omtn_2019_07_014
crossref_primary_10_2174_1568026620666200128142603
crossref_primary_10_1016_j_cbi_2017_09_006
crossref_primary_10_1021_acs_chemrev_5b00046
crossref_primary_10_1016_j_phrs_2020_105231
crossref_primary_10_1039_C8NH00417J
Cites_doi 10.1016/S0076-6879(03)72019-9
10.1016/0005-2736(94)90003-5
10.1016/0169-409X(95)00022-Y
10.1016/S0168-3659(01)00330-3
10.1515/BC.2003.044
10.1016/j.ijpharm.2009.02.022
10.1007/BF00046364
10.1126/science.8128245
10.1021/bc060080h
10.1021/bc0155061
10.1021/bc025517+
10.1016/S0168-3659(01)00309-1
10.1016/j.addr.2012.08.009
10.1158/1078-0432.CCR-08-2392
10.1073/pnas.0931428100
10.1021/mp8001528
10.1021/bc060228x
10.1016/S0005-2728(01)00165-7
10.1038/mt.2008.36
10.1007/s11095-006-9662-5
10.1208/s12248-010-9174-4
10.1080/10717540902937562
10.1016/j.addr.2013.08.004
10.1080/10258140290033066
10.1016/j.bmcl.2005.07.087
10.1016/0014-2999(90)91262-A
10.1016/S0928-0987(00)00166-4
10.1016/j.jhep.2004.12.035
10.1016/0092-8674(88)90263-2
10.1080/10611860701498203
10.1042/BJ20040238
10.1016/S1368-7646(03)00082-7
10.1016/S0168-3659(99)00248-5
10.1124/jpet.107.127704
10.1016/j.ddmec.2004.10.001
10.1073/pnas.151247498
10.1016/j.jconrel.2011.12.002
10.1021/bc900081e
10.1208/s12248-008-9029-4
10.1208/aapsj0902015
10.1016/j.jconrel.2004.08.007
10.1158/1078-0432.CCR-07-4973
10.1038/nrd1632
10.3109/10717544.2011.567310
10.1016/0005-2736(91)90246-5
10.1158/0008-5472.CAN-05-0765
10.1016/j.taap.2004.10.012
10.3727/000000006783980946
10.1039/c2ib20135f
10.1016/S0021-9258(18)37555-0
10.1016/j.ejpb.2008.09.026
10.1016/j.molmed.2012.04.012
ContentType Journal Article
Copyright Copyright © 2014 Landes Bioscience 2014
Copyright_xml – notice: Copyright © 2014 Landes Bioscience 2014
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.4161/cbt.26609
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1555-8576
EndPage 80
ExternalDocumentID 10_4161_cbt_26609
24145298
10926609
Genre Research Paper
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA121838
– fundername: NCI NIH HHS
  grantid: R01 CA128486
GroupedDBID ---
00X
0R~
0YH
29B
30N
53G
5GY
6J9
AAAVI
AAJNR
ABBKH
ABCCY
ABEIZ
ABFIM
ABJVF
ACENM
ACGFO
ACGFS
ACTIO
ADBBV
ADCVX
AECIN
AEGYZ
AEISY
AENEX
AEXWM
AHDLD
AIJEM
AIRBT
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
AQRUH
AVBZW
AWQZV
BABNJ
BAWUL
BLEHA
CCCUG
DGEBU
DIK
DKSSO
E3Z
EBS
EJD
EMOBN
F5P
H13
HYE
IH2
IPNFZ
KSSTO
KYCEM
M4Z
O9-
OK1
P2P
P6G
RIG
RPM
SJN
TFL
TFT
TFW
TR2
TTHFI
ZGOLN
0VX
4.4
ACKZS
ADFZZ
AFPKN
AGYJP
AURDB
BFWEY
C1A
CGR
CUY
CVF
CWRZV
ECM
EIF
GROUPED_DOAJ
LJTGL
NPM
PCLFJ
TDBHL
UDS
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c420t-95cd2aad6c5eb80611bf461e87d20244bbc0e91e0483ed37fef1b1577fc82b973
IEDL.DBID RPM
ISSN 1538-4047
IngestDate Tue Sep 17 21:26:03 EDT 2024
Sat Oct 05 04:36:06 EDT 2024
Fri Aug 23 03:20:08 EDT 2024
Sat Sep 28 07:52:47 EDT 2024
Tue Jul 04 18:14:25 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords multidrug resistance
2C5 mAb
Lipodox
doxil
SKOV-3 cells
TAT peptide
pH-sensitive polymers
multifunctional immunoliposomes
doxorubicin
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-95cd2aad6c5eb80611bf461e87d20244bbc0e91e0483ed37fef1b1577fc82b973
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.tandfonline.com/doi/pdf/10.4161/cbt.26609?needAccess=true
PMID 24145298
PQID 1493796652
PQPubID 23479
PageCount 12
ParticipantIDs crossref_primary_10_4161_cbt_26609
proquest_miscellaneous_1493796652
informaworld_taylorfrancis_310_4161_cbt_26609
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3938525
pubmed_primary_24145298
PublicationCentury 2000
PublicationDate 2014-01-01
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer biology & therapy
PublicationTitleAlternate Cancer Biol Ther
PublicationYear 2014
Publisher Taylor & Francis
Landes Bioscience
Publisher_xml – name: Taylor & Francis
– name: Landes Bioscience
References 2292138 - Cancer Metastasis Rev. 1990 Nov;9(3):253-66
21438724 - Drug Deliv. 2011 Jul;18(5):377-84
16168650 - Bioorg Med Chem Lett. 2005 Nov 15;15(22):5071-5
8128245 - Science. 1994 Mar 18;263(5153):1600-3
19446767 - Int J Pharm. 2009 Jun 5;374(1-2):114-8
2065067 - Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36
19601640 - Bioconjug Chem. 2009 Aug 19;20(8):1531-7
15845415 - Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37
9393743 - Cancer Res. 1997 Dec 1;57(23):5246-53
23973912 - Adv Drug Deliv Rev. 2013 Nov;65(13-14):1748-62
15491817 - J Control Release. 2004 Nov 5;100(1):135-44
12715889 - Biol Chem. 2003 Mar;384(3):387-93
17913043 - Oncol Res. 2007;16(8):351-9
22964425 - Adv Drug Deliv Rev. 2013 Jan;65(1):24-35
16848401 - Bioconjug Chem. 2006 Jul-Aug;17(4):943-9
15688077 - Nat Rev Drug Discov. 2005 Feb;4(2):145-60
18483388 - Clin Cancer Res. 2008 May 15;14(10):3193-203
10699287 - J Control Release. 2000 Mar 1;65(1-2):271-84
12378272 - Cell Mol Biol Lett. 2002;7(3):889-94
22682515 - Trends Mol Med. 2012 Jul;18(7):385-93
12121127 - Bioconjug Chem. 2002 Jul-Aug;13(4):729-36
18977297 - Eur J Pharm Biopharm. 2009 Mar;71(3):431-44
19538007 - Drug Deliv. 2009 Jul;16(5):261-7
22182771 - J Control Release. 2012 Jun 10;160(2):264-73
19049322 - Mol Pharm. 2009 Jan-Feb;6(1):246-54
17947497 - J Pharmacol Exp Ther. 2008 Jan;324(1):95-102
18388927 - Mol Ther. 2008 May;16(5):893-900
7641188 - Cancer Res. 1995 Sep 1;55(17):3752-6
3182782 - J Biol Chem. 1988 Nov 5;263(31):16051-4
11716691 - Bioconjug Chem. 2001 Nov-Dec;12(6):995-9
15826724 - J Hepatol. 2005 May;42(5):736-43
15193145 - Biochem J. 2004 Sep 15;382(Pt 3):945-56
14610822 - Methods Enzymol. 2003;372:339-49
11286983 - Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411
17614355 - AAPS J. 2007;9(2):E128-47
16550475 - Pharm Res. 2006 Apr;23(4):752-8
14643297 - Drug Resist Updat. 2003 Oct;6(5):271-9
11489482 - J Control Release. 2001 Jul 6;74(1-3):47-61
16103050 - Cancer Res. 2005 Aug 15;65(16):7045-51
17309227 - Bioconjug Chem. 2007 Mar-Apr;18(2):363-70
19276264 - Clin Cancer Res. 2009 Mar 15;15(6):1973-80
12716967 - Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44
11489491 - J Control Release. 2001 Jul 6;74(1-3):147-58
2849510 - Cell. 1988 Dec 23;55(6):1189-93
18587651 - AAPS J. 2008 Jun;10(2):349-59
22869005 - Integr Biol (Camb). 2013 Jan;5(1):96-107
11438707 - Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91
12385965 - J Biochem Mol Biol Biophys. 2002 Oct;6(5):309-14
20143195 - AAPS J. 2010 Jun;12(2):171-80
17671900 - J Drug Target. 2007 Aug-Sep;15(7-8):538-45
11033430 - Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91
7918551 - Biochim Biophys Acta. 1994 Oct 12;1195(1):11-20
R21
Gupta B (R37) 2007; 16
R20
R23
R25
R24
R27
R26
R29
R28
R1
R2
R3
R4
R5
R6
R7
R9
R30
R32
R31
R34
R33
R36
R35
R38
Yuan F (R22) 1995; 55
R39
Elbayoumi T (R54) 2006; 26
Maeda H (R18) 1988; 263
R41
R40
R43
R42
R45
R47
R46
R49
R48
R50
R52
Krishna R (R8) 1997; 57
R51
R10
Allen TM (R44) 2002; 7
R53
R12
R56
R11
R55
R14
R13
R16
R15
R17
R19
References_xml – ident: R35
  doi: 10.1016/S0076-6879(03)72019-9
– ident: R23
  doi: 10.1016/0005-2736(94)90003-5
– ident: R24
  doi: 10.1016/0169-409X(95)00022-Y
– ident: R13
  doi: 10.1016/S0168-3659(01)00330-3
– ident: R32
  doi: 10.1515/BC.2003.044
– volume: 55
  start-page: 3752
  year: 1995
  ident: R22
  publication-title: Cancer Res
  contributor:
    fullname: Yuan F
– ident: R36
  doi: 10.1016/j.ijpharm.2009.02.022
– ident: R21
  doi: 10.1007/BF00046364
– ident: R2
  doi: 10.1126/science.8128245
– volume: 26
  start-page: 1
  year: 2006
  ident: R54
  publication-title: Pharmaceutical Engineering
  contributor:
    fullname: Elbayoumi T
– ident: R41
  doi: 10.1021/bc060080h
– ident: R48
  doi: 10.1021/bc0155061
– ident: R45
  doi: 10.1021/bc025517+
– ident: R20
  doi: 10.1016/S0168-3659(01)00309-1
– ident: R26
  doi: 10.1016/j.addr.2012.08.009
– ident: R56
  doi: 10.1158/1078-0432.CCR-08-2392
– ident: R29
  doi: 10.1073/pnas.0931428100
– ident: R52
  doi: 10.1021/mp8001528
– ident: R40
  doi: 10.1021/bc060228x
– ident: R28
  doi: 10.1016/S0005-2728(01)00165-7
– ident: R30
  doi: 10.1038/mt.2008.36
– ident: R50
  doi: 10.1007/s11095-006-9662-5
– ident: R12
  doi: 10.1208/s12248-010-9174-4
– ident: R14
  doi: 10.1080/10717540902937562
– ident: R15
  doi: 10.1016/j.addr.2013.08.004
– ident: R9
  doi: 10.1080/10258140290033066
– ident: R16
  doi: 10.1016/j.bmcl.2005.07.087
– ident: R5
  doi: 10.1016/0014-2999(90)91262-A
– ident: R1
  doi: 10.1016/S0928-0987(00)00166-4
– ident: R11
  doi: 10.1016/j.jhep.2004.12.035
– ident: R31
  doi: 10.1016/0092-8674(88)90263-2
– ident: R39
  doi: 10.1080/10611860701498203
– volume: 7
  start-page: 889
  year: 2002
  ident: R44
  publication-title: Cell Mol Biol Lett
  contributor:
    fullname: Allen TM
– ident: R46
  doi: 10.1042/BJ20040238
– ident: R10
  doi: 10.1016/S1368-7646(03)00082-7
– ident: R19
  doi: 10.1016/S0168-3659(99)00248-5
– ident: R51
  doi: 10.1124/jpet.107.127704
– ident: R6
  doi: 10.1016/j.ddmec.2004.10.001
– ident: R53
  doi: 10.1073/pnas.151247498
– ident: R42
  doi: 10.1016/j.jconrel.2011.12.002
– volume: 57
  start-page: 5246
  year: 1997
  ident: R8
  publication-title: Cancer Res
  contributor:
    fullname: Krishna R
– ident: R38
  doi: 10.1021/bc900081e
– ident: R47
  doi: 10.1208/s12248-008-9029-4
– ident: R3
  doi: 10.1208/aapsj0902015
– ident: R27
  doi: 10.1016/j.jconrel.2004.08.007
– ident: R55
  doi: 10.1158/1078-0432.CCR-07-4973
– ident: R17
  doi: 10.1038/nrd1632
– ident: R34
  doi: 10.3109/10717544.2011.567310
– ident: R49
  doi: 10.1016/0005-2736(91)90246-5
– ident: R4
  doi: 10.1158/0008-5472.CAN-05-0765
– ident: R7
  doi: 10.1016/j.taap.2004.10.012
– volume: 16
  start-page: 351
  year: 2007
  ident: R37
  publication-title: Oncol Res
  doi: 10.3727/000000006783980946
  contributor:
    fullname: Gupta B
– ident: R43
  doi: 10.1039/c2ib20135f
– volume: 263
  start-page: 16051
  year: 1988
  ident: R18
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)37555-0
  contributor:
    fullname: Maeda H
– ident: R25
  doi: 10.1016/j.ejpb.2008.09.026
– ident: R33
  doi: 10.1016/j.molmed.2012.04.012
SSID ssj0027269
Score 2.3552244
Snippet Multidrug resistance (MDR) is a hallmark of cancer cells and a crucial factor in chemotherapy failure, cancer reappearance, and patient deterioration. We have...
SourceID pubmedcentral
proquest
crossref
pubmed
informaworld
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 69
SubjectTerms 2C5 mAb
Animals
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - chemistry
Antibodies, Monoclonal - chemistry
Apoptosis - drug effects
Cell Line, Tumor
Cell Survival - drug effects
doxil
doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Doxorubicin - chemistry
Drug Resistance, Neoplasm
Female
Heterografts
Humans
Lipodox
Male
Mice
Mice, Inbred BALB C
Mice, Nude
multidrug resistance
multifunctional immunoliposomes
Nucleosomes - immunology
Nucleosomes - metabolism
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - immunology
Ovarian Neoplasms - pathology
pH-sensitive polymers
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - chemistry
Research Paper
SKOV-3 cells
tat Gene Products, Human Immunodeficiency Virus - chemistry
TAT peptide
Title Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models
URI https://www.tandfonline.com/doi/abs/10.4161/cbt.26609
https://www.ncbi.nlm.nih.gov/pubmed/24145298
https://search.proquest.com/docview/1493796652
https://pubmed.ncbi.nlm.nih.gov/PMC3938525
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEF3iHEovpd91P8K29Lq2pN3VSseQNoSCQw8O5Cb2MxVEkrHk0J_Un9mZlRXiklNBF2sly_BGnvd2Z98Q8lWVAf2PPeMus0xwnTADocLSEGSRF0WqBW4UXl3mF1fix7W8PiJy2gsTi_atqRftbbNo61-xtnLT2OVUJ7b8uTrjJS9kJpczMoMAnST6pLKy2McuvskiEWq0E0Iev7RmWEBCStAqFDIXrjkWB_nowK30Mc75b-nkg1x0_pw825NIejr-2BfkyLcvyZPVfpn8FfnzrfvdbXcGP1I41qdrusHyFedZ07k6AO-ksZQQ09o4G0hr3CnS3dabru8a31PnG-SOaCXRw5cgu-zhNtwIgf0mqL7RNYxTA1hTt93dsB6L4fHvk-rWjadAzCNBbQfa3YEq1y21GGZbGjvw9K_J1fn39dkF27dkYFZkycBKaV2mtcut9KYALpCaIPLUF8plkO2FMTbxZerRqN47roIPqUmlUsEWmSkVf0OO26717wjVOi91AfotWCWMFYYnmQX16JUBilnKOfkyAVNtRueNChQLAlkBkFUEck7YQ8iqIU5zhLEnScUfuf7zhGkF7xEujujWd7seJBAQNdB-MpuTtyPG94-dYmVO1AH69xegR_fhCIRu9Oreh-r7_77zA3kKHE2Msz4fyfGw3flPwIMGc0JmPLk8idH_F26mEBA
link.rule.ids 230,315,730,783,787,888,27936,27937,53804,53806,60214,61003
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqVgIupTy7UMAgrl7ycOLkWAHVAt09bUVvke3YJYKNV3kg1F_Ez2Qm3i1N1UulXBLn4TgzmW_smW8IeS9yi_zHhsVlpBmPZcAUiAoLrU2yNMtCyTFReL5IZ2f863lyvkPSbS4MhlWiD209UcTwr0blxslo1HDE4x-06qZgWDBvby9F0i9M3QgW_x2taChlNygzD7jwjELjS0d2aMRSehvWvBkyec0GnTwk37e996EnP6d9p6b68gax491f74Dsb2ApPfZy9IjsmPoxuTffLLw_IX8_uT-u6RXuUtiWx0u6xoCY0rCVKysLSJYOwYloKP38Iq0w98T9qtaudSvT0tKsEI0iOUULN0G82sJlmFqBFSyovJAVtFMF0kPLpr9gLYbX4w-Zwtv4Q41pEfLWHXW_wc-XNdUouA0davq0T8nZyeflxxnbFHlgmkdBx_JEl5GUZaoTozJAF6GyPA1NJsoI8ANXSgcmDw1S35syFtbYUIWJEFZnkcpF_Izs1q42h4RKmeYyA4_QasGV5ioOIg3-qBEKQGueTMi77Scv1p7LowAfCMe8gDEvhjGfEHZdGIpumDixvspJEd9y_tuttBSgmbjcImvj-hacKoB-4E0m0YQ899Jz9VjATbjinU2IGMnV1QnI-j1uqasfA_t3nMdZEiUv7tjPN-T-bDk_LU6_LL69JA8A93E_k3REdrumN68AW3Xq9aBI_wAGuSlw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JbtswECWCFAh66b443diiV7paSFE6Bk2NdInRg1PkJnBNhNaSYUlB0S_qZ3ZGtNMoyCWAL7YWS9QbzRty5g0h72XhUf_YsdQmhvFURUwDVFjsvcizPI8Vx0Lh43l2dMK_nIrTHSK2tTCYVokxtA9CEcO7Go17ZT0aONLxD0Z3U_ArWLZ3B7x_hPBOo_n_OCsZOtkNtswjLoOg0PjQkRsaiZTeRDWvZ0xecUGz--TH9uJD5snPad_pqflzTdfx1nf3gNzbkFJ6EFD0kOy4-hHZO94suz8mfw-b38261_iVwmdxsKArTIexji0bW3ngsXRITUQ3GWYXaYWVJ82vatW0zdK11LolclGUpmjhJMhWWzgMCyuwfwVVZ6qC7VQDdqhd92esxeR6fB1TuJnw09q1SHjrjjYXEOWrmhqE7ZoOHX3aJ-Rk9mnx8YhtWjwww5OoY4UwNlHKZkY4nQO3iLXnWexyaRNgD1xrE7kidih872wqvfOxjoWU3uSJLmT6lOzWTe2eE6pUVqgc4kFvJNeG6zRKDESjTmqgrIWYkHfbJ16ugpJHCREQjnkJY14OYz4h7CoWym6YNvGhx0mZ3rD_2y1YSrBLXGxRtWv6FkIqIH4QS4pkQp4F8Fz-LbAmXO_OJ0SOYHW5A2p-j7fU1fmg_Z0WaS4SsX_L63xD9r4fzspvn-dfX5C7QPp4mEZ6SXa7de9eAbHq9OvBjP4BhqEoHQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Doxorubicin+in+TAT+peptide-modified+multifunctional+immunoliposomes+demonstrates+increased+activity+against+both+drug-sensitive+and+drug-resistant+ovarian+cancer+models&rft.jtitle=Cancer+biology+%26+therapy&rft.au=Apte%2C+Anjali&rft.au=Koren%2C+Erez&rft.au=Koshkaryev%2C+Alexander&rft.au=Torchilin%2C+Vladimir+P&rft.date=2014-01-01&rft.pub=Taylor+%26+Francis&rft.issn=1538-4047&rft.eissn=1555-8576&rft.volume=15&rft.issue=1&rft.spage=69&rft.epage=80&rft_id=info:doi/10.4161%2Fcbt.26609&rft.externalDocID=10926609
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-4047&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-4047&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-4047&client=summon